SMAD3 and renal fibrosis: In preclinical studies, I-BET151 has been shown to inhibit the activation of the TGF-β/Smad3, STAT3, ERK1/2, and NF-kB signaling pathways in renal fibrosis and to reverse renal EMT [242, 243].